Super Micro Computer Stock (SMCI) Bulls Eye $100 Price Target
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Even so, SMCI's strong growth outlook and attractive valuation point to a potential rebound. If the company can navigate near-term challenges, a return to previous highs remains well within reach.
Fueling the Surge: The AI Boom
Over the past five years, SMCI has ridden the trend of artificial intelligence and data center expansion with its customizable, high-efficiency servers becoming critical for enterprises and hyperscalers scaling AI infrastructure.
To quantify this trend, note that from 2020 to 2024, SMCI's revenue soared from $3.34 billion to $15 billion, with a 110.42% year-over-year leap in 2024 alone, driven by partnerships with NVIDIA (NVDA) and AMD (AMD). In the meantime, its U.S.-based manufacturing and leadership in liquid-cooling technology have further solidified its edge, meeting the market's push for sustainable, high-performance solutions.
Wall Street has grown increasingly bullish on SMCI, thanks to its ability to deliver modular, scalable systems that have made it a top choice for cloud providers and AI-focused companies. Its inclusion in the NASDAQ 100 in 2023 further elevated its profile and fueled investor optimism.
That momentum hasn't faded. With the global data center market projected to hit $528 billion this year and grow at a high-single-digit pace through the decade, SMCI stands to benefit significantly. Its innovative product lineup positions it well to capture a sizable share of this expanding market.
SMCI Arrests Stock Market Slide
Despite the strong long-term themes supporting SMCI and a solid base of bullish investors, the stock has faced serious headwinds since reaching its 2024 peak. A critical report last year resurfaced concerns over accounting practices, echoing a 2018 SEC probe that resulted in fines and a temporary NASDAQ delisting. The fallout was swift: shares plunged nearly 85% at their lowest point. Investor confidence was further rattled by a delayed 10-K filing, raising fears of another potential delisting, while ongoing investigations by the DOJ and SEC cast an even darker cloud.
The effect on SMCI's share price has been significant. As TipRanks data shows, SMCI's performance against the broader S&P 500 (SPX) benchmark has been lackluster to say the least. SMCI has lagged the S&P by over 40%.
Operational challenges have added to the pressure. SMCI's most recent quarterly results fell short of expectations, with revenue coming in at $4.6 billion versus a forecasted $5 billion. Adjusted EPS dropped to $0.31 from $0.66 a year earlier, hit by inventory write-downs on older-generation GPUs and customer delays tied to the transition to NVIDIA's Blackwell architecture.
Gross margins shrank to 9.7%, down 220 basis point s from the previous quarter, due to rising costs and a mix shift toward lower-margin hyperscale contracts. Meanwhile, a $2 billion convertible note offering raised dilution concerns, further weighing on sentiment.
Robust Growth Prospects: A Bright Horizon
Despite recent setbacks, SMCI has now addressed its accounting concerns, and its long-term growth outlook remains firmly intact, driven by the ongoing surge in AI infrastructure demand. Even with last quarter's top-line miss, revenue still climbed 19% year-over-year, with AI GPU platforms making up over 70% of total sales—a clear sign of strong adoption among enterprise clients and cloud providers.
CEO Charles Liang emphasized SMCI's first-mover advantage with next-gen GPU platforms and its Datacenter Building Block Solutions (DCBBS), which are expected to power growth as customers transition to technologies like NVIDIA's Blackwell architecture starting in Q4 2025.
The company is also expanding aggressively, building out facilities in Malaysia, Taiwan, and Europe to keep pace with global demand. Its upcoming DLC-2 liquid-cooling solution and strategic partnerships with NVIDIA and Ericsson on edge AI infrastructure further strengthen its competitive position in the $367 billion data center market.
Reflecting this momentum, management is guiding for Q4 2025 revenue between $5.6 billion and $6.4 billion, with adjusted EPS of $0.40 to $0.50, signaling confidence in both margin recovery and production scale-up.
A Bargain with Upside Potential
At today's share price, SMCI trades at 23x this year's expected EPS of $2.08, a compelling multiple given its growth trajectory. At the same time, analysts forecast EPS growth of 34% in 2026 and 28% in 2027, which is to be driven by AI demand and improving supply chains. So SMCI's forward P/Es quickly fall to mid-teens below $50 per share, which means that as SMCI achieves these targets, investors are likely to chase the stock higher.
So yes, risks remain, including rising competition and potential tariff impacts. Still, the broader AI and data center trends remain powerful tailwinds, with SMCI's leadership in high-efficiency servers and cooling systems aligning with market demand.
Is SMCI Stock a Good Buy?
Analyst sentiment on SMCI is currently mixed, reflecting a divide between those who view it as a value opportunity and those who remain cautious. The stock holds a Moderate Buy consensus, based on six Buy, six Hold, and two Sell ratings issued over the past three months.
Notably, SMCI's average 12-month price target stands at $42.67, implying about 13% downside from current levels. This suggests that, unlike my more optimistic outlook, Wall Street isn't yet convinced the stock is on track to reclaim its previous highs.
SMCI Set for Rebound as Wall Street Remains Unconvinced
Despite recent volatility, SMCI continues to play a vital role in the AI infrastructure landscape, backed by strong fundamentals, accelerating demand, and an attractive valuation. Its leadership in next-generation server and cooling technologies, expanding global presence, and strategic partnerships position the company well for long-term growth.
Now that its accounting concerns are resolved and margin pressures appear set to ease, SMCI looks poised to regain lost ground. While Wall Street's conviction in the stock remains lukewarm for now, the underlying story suggests meaningful upside for those willing to look past the near-term noise.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Could Buying Nvidia Today Set You Up for Life?
The AI boom isn't over for Nvidia. But the laws of large numbers could make it difficult for the stock to repeat its mind-blowing past returns. Nvidia remains a potential market beater, but is it also a millionaire maker? That's more complicated. 10 stocks we like better than Nvidia › There were likely many investors who hadn't heard of, or at least weren't familiar with, Nvidia (NASDAQ: NVDA) five years ago. Then came ChatGPT in late 2022, and the market rally around artificial intelligence (AI) from 2023 onward put the GPU chip company squarely on the map. Nvidia has come to dominate the market for chips used in AI data centers, unleashing life-changing investment returns in the process. Nvidia stock has returned 1,500% over just the past five years. It's rarely too late to invest in a great business, but can buying Nvidia right now still set you up for life? Here is what you need to know. AI is a bit of an arms race in the technology world. Companies are spending billions to build vast data centers housing thousands of servers and computer chips that work together to train and operate increasingly advanced AI models quickly, and at a growing scale. Nvidia dominates this market, with an estimated 92% market share. Why so high? Nvidia planted the seeds for its dominance years ago; its CUDA programming language optimizes its GPU chips, which already excel at handling heavy workloads, for AI. That one-two punch of high-end hardware and efficient software took the AI chip market by storm. Even if competitors start to make some headway, the broader AI opportunity is growing so rapidly that Nvidia continues to pile up chip sales at breakneck speed. Research from McKinsey estimates that global data center spending for AI will exceed $5 trillion over the next five years alone, as companies continue to invest in infrastructure to support a world increasingly adopting AI. That doesn't even begin to scratch the surface of adjacent AI opportunities, including those that require localized computing resources, such as humanoid robotics or autonomous vehicles. In other words, AI won't live in data centers forever. Nvidia already has its eyes on the future with hardware and software ecosystems in motion for developers across these early-stage market segments. So, while it's one thing to say that Nvidia could sustain its massive AI sales from these past several years, it's another thing to anticipate enough incremental growth on top of that to make the stock a life-changing investment from its current valuation. The company recently made headlines as the first company to attain a $4 trillion market capitalization. For a stock that has risen 1,500% over the past five years, it wouldn't seem unrealistic for Nvidia's price to double at some point. But even that would push Nvidia's value to $8 trillion. Huge numbers eventually start to succumb to gravitational effects. At $8 trillion, Nvidia would be roughly one-eighth of the total value of all U.S. stocks. It would be almost as large as the combined value of every publicly traded Chinese company, and larger than the stock market of every other country. So, when you start projecting such a large company to double, triple, or grow enough to set you up for life, the numbers quickly go to eye-popping levels. To be clear, Nvidia's business doesn't appear to have peaked, and there could easily be some solid investment upside left. Shares still trade at roughly 39 times 2025 earnings estimates, which is a reasonable valuation for a company that analysts anticipate will grow earnings by an average of 28% annually over the next three to five years. That said, Nvidia is likely too large now to replicate its past investment returns. Low-double-digit annualized returns seem more realistic, making Nvidia a fantastic addition to a diversified portfolio, just not the life-altering stock it has been to this point. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 14, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Could Buying Nvidia Today Set You Up for Life? was originally published by The Motley Fool Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "Henry Schein has been my professional home for 45 years and I will conclude this chapter of my life with enormous gratitude for the opportunity to serve as CEO and with great confidence in the Company's future,' said Stanley M. Bergman. 'With the progress made advancing our BOLD+1 strategic plan and with strong management in place, it is the right time for me to retire at the end of the year,' Mr. Bergman said. 'I look forward to working with the Board to identify my successor and effect a smooth transition. Henry Schein has been my professional home for 45 years and I will conclude this chapter of my life with enormous gratitude for the opportunity to serve as CEO and with great confidence in the Company's future.' Philip A. Laskawy, Lead Director for Henry Schein said, 'Under Stan's leadership, Henry Schein has become the global leader in providing dental and medical products and solutions for health care providers in alternate care settings, and we recognize the significant impact he has had on the Company and the entire health care industry. We owe a tremendous debt of gratitude to Stan for his steadfast devotion to Henry Schein and for bringing his unique blend of strategic vision, attention to detail, and entrepreneurship to the Company.' During Mr. Bergman's tenure as CEO, Henry Schein's revenue grew from $225 million in 1989 to almost $13 billion in 2024, representing an approximate compound annual growth rate of 17.5%, while the Company's market capitalization grew from $290 million at the time of its IPO in 1995 to a current value of almost $9 billion 1. Further, Henry Schein has delivered a non-GAAP EPS CAGR of 12.4% over this same period 2. Among Mr. Bergman and the team's many accomplishments, the Company transformed itself multiple times: growing from what was a small, U.S.-based primarily dental mail order company to becoming the largest global full service dental distributor of products and services and a leading medical distributor to alternate care sites with a growing presence in home-delivered products; building what is now the largest provider of global dental practice management software and digital services; creating a fast-growing dental specialties business, including the 2 nd -largest provider of endodontic products and 3 rd -largest provider of dental implant and bone regeneration products; significantly growing the contribution from its higher growth, higher margin businesses and corporate-brand products under its BOLD+1 strategic plan to over 50% of total non-GAAP operating income 3; and establishing Henry Schein as a global leader in advancing public-private partnerships to support access to care for underserved individuals, strengthening infrastructure for disaster relief and pandemic preparedness, and elevating the role of oral health as a key part of systemic health and wellness. 'It has been my greatest privilege to lead Team Schein over the past 35-plus years. Guided by our purpose-driven mission, we have built an agile Company that is able to meet the changing needs of our customers, has created significant shareholder value, and is well positioned for the future. As part of succession planning, the Company has focused on developing the next generation of leaders and earlier this year simplified the business by separating into three operating divisions, each with outstanding leadership. I fully expect that Andrea Albertini, CEO of the Global Distribution Group who also has responsibility for the Global Technology Group, and Tom Popeck, CEO of the Health Care Specialties Group, together with the rest of the Company's Executive Management Committee, will elevate Henry Schein to new heights by continuing to advance the BOLD+1 strategy and working with KKR on value creation initiatives and a broad-based employee ownership program,' Mr. Bergman said. Mr. Bergman sent out a letter this morning in which he thanked all of Team Schein for playing such an important part of building a unique company. He wrote in part: 'I am especially pleased to have worked with tens of thousands of incredibly committed and talented Team Schein Members who helped reimagine and reinvent Henry Schein's role, from one of product delivery and logistics to one whose mission today is to help our over 1 million health care professionals operate better and more efficient practices so our customers can concentrate on delivering the best quality patient care.' Mr. Bergman concluded his letter by thanking many people who stood by his side during the journey, including senior management, the Board, the Schein family, and others. 'With the team continuing to balance the Company's five constituents that make up the Henry Schein Mosaic of Success (suppliers, customers, investors, employees, and society at large) and maintaining the values of Team Schein, I believe that Henry Schein's best years are yet to come,' Mr. Bergman continued. About Henry Schein, Inc. Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at and @HenrySchein on X. Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the 'Safe Harbor' provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as 'may,' 'could,' 'expect,' 'intend,' 'believe,' 'plan,' 'estimate,' 'forecast,' 'project,' 'anticipate,' 'to be,' 'to make' or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025; our ability to develop or acquire and maintain and protect new products (particularly technology products) and services and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, ongoing wars, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies, changes to other economic indicators and international trade agreements; the threat or outbreak of war, terrorism or public unrest (including, without limitation, the war in Ukraine, the Israel-Gaza war and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions, including the current imposition of additional new tariffs by the U.S. on numerous countries, retaliatory tariffs and potential for additional retaliatory tariffs; greater restrictions on imports and exports; supply chain disruption; geopolitical wars; failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law. Included within the press release are non-GAAP financial measures that supplement the Company's Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company's actual results prepared under GAAP to exclude certain items. In the schedule attached to the press release, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. The impact of certain items that are excluded include integration and restructuring costs, and amortization of acquisition-related assets, because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate and occur on an unpredictable basis. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Exhibit * Average annual increase (1) In 1995, Operating Income, Net Income and Diluted EPS were negative, and CAGR amounts cannot be calculated. Using 1996 as a base year the CAGR for Operating Income, Net Income and Diluted EPS was 15.08%, 17.15%, and 14.23%, respectively. For 1996, there we no reconciling items on a GAAP to Non-GAAP basis. Note: Amounts may not sum due to rounding. Expand ___________________________ 1 This excludes the Company's 2019 spin-off of its animal health business to a separate publicly held company which had an initial market capitalization of over $4 billion. 2 From Continuing Operations, based on 12-month data through Q4 2024. Excludes certain non-recurring items to provide a more comparable basis for analysis. A reconciliation of GAAP to non-GAAP adjustments is included as an Exhibit to this press release. CAGRs are calculated as of December 28, 2024. 3 The Company is unable to calculate the GAAP operating income contribution without unreasonable effort, so it is not including it in the reconciliation. Expand Expand
Business Wire
an hour ago
- Business Wire
Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird's Biotech Discovery Series. A live webcast of the event will be accessible by visiting the 'Events and Presentations' section on the 'Investors' page of Enanta's website at A replay of the webcast will be available following the event and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information.
